XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Intangibles, Net and Goodwill
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles, Net and Goodwill Intangibles, Net and Goodwill
Intangibles, net, consisted of the following:
 December 31, 2022
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(12,061)$1,479 
Customer relationships
15 - 25
Accelerated96,681 (95,009)1,672 
Currently marketed product
9 - 15
Straight-Line275,700 (47,628)228,072 
Licenses
11 - 16
Straight-Line85,800 (19,101)66,699 
Developed technology9Straight-Line2,400 (677)1,723 
IPR&DN/AN/A15,640 — 15,640 
Total$489,761 $(174,476)$315,285 

December 31, 2021
(in thousands)Useful Lives (in years)Amortization
Method		CostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,510)$2,030 
Customer relationships
15 - 25
Accelerated96,880 (94,630)2,250 
Currently marketed product
15
Straight-Line275,700 (23,345)252,355 
Licenses
11 - 16
Straight-Line85,800 (11,555)74,245 
Developed technology9Straight-Line2,400 (410)1,990 
IPR&DN/AN/A15,640 — 15,640 
Total$489,960 $(141,450)$348,510 
The Company recorded amortization expense for its intangible assets of $33.2 million, $27.5 million and $10.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.
In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.
The Company performed its annual impairment test of its IPR&D intangible assets as of October 31, 2020. As a result of a timing delay in the development of an AZEDRA IPR&D intangible asset due to the impact of COVID-19, the Company determined that the carrying value of $18.3 million exceeded the fair value of the asset. Accordingly, the Company recorded a non-cash impairment charge of $2.7 million for the year ended December 31, 2020 in research and development expenses in the consolidated statements of operations. The estimated fair value of the AZEDRA IPR&D intangible asset was determined based on the present values of the expected cash flows. The Company used a discount rate of 23.0% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.
The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:
(in thousands)Amount
2023$32,638 
202432,563 
202532,508 
202632,497 
202732,482 
2028 and thereafter 136,957 
Total$299,645 
Changes in the carrying amounts of goodwill for the years ended December 31, 2022 and 2021, were as follows:

 December 31,
(in thousands)20222021
Balance, Beginning of year$61,189 $58,632 
Increase from acquisition— 2,557 
Balance, End of year$61,189 $61,189